Recurrent Adult Hodgkin Lymphoma Clinical Trial
Official title:
A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
Verified date | March 2021 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did not respond to previous therapy. Bortezomib is an inhibitor of protein degradation. Bortezomib degrades short-lived regulatory proteins in the cell, and has been reported to increase the tumor cells. Bortezomib may increase the effectiveness of ifosfamide and vinorelbine (two standard drugs given to children with Hodgkin Lymphoma that has come back after initial treatment) by making cancer cells more sensitive to effectiveness of standard chemotherapy by preventing anti-death responses in these drugs. Giving bortezomib together with ifosfamide and vinorelbine tartrate should kill more cancer cells than are killed with ifosfamide and vinorelbine alone.
Status | Completed |
Enrollment | 26 |
Est. completion date | December 31, 2016 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 29 Years |
Eligibility | Inclusion Criteria: - Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria: - Stage I-IV disease - No morphologically unclassifiable disease - Meets 1 of the following criteria: - Mixed cellularity - Lymphocytic depletion (LD) - LD, diffuse fibrosis - LD, reticular - Lymphocyte predominance (LP) - LP, diffuse - LP, nodular - Nodular sclerosis (NS) - NS, cellular phase - NS, lymphocytic predominance - NS, mixed cellularity - NS, LD - Not otherwise specified - Primary refractory disease OR disease in first relapse, except for the following: - Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy - Patients on the observation-only arm of protocol COG-AHOD0431 - Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney) - Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met: - Platelet count = 20,000/mm³ (platelet transfusion allowed) - Hemoglobin = 8 g/dL (packed red blood cell transfusion allowed) - Karnofsky performance status (PS) 60-100% (for patients > 16 years of age) OR Lanksy PS 60-100% (for patients =< 16 years of age) - Life expectancy >= 2 months - Absolute neutrophil count >= 1,000/mm^3 - Platelet count >= 75,000/mm^3 (transfusion independent) (for patients with no bone marrow involvement) - Creatinine =< 1.5 times upper limit of normal (ULN) - Creatinine clearance or radioisotope glomerular filtration rate >= 70 mL/min/1.73 m^2 - AST and ALT =< 2.5 times ULN - Bilirubin =< 1.5 times ULN - Shortening fraction >= 27% by echocardiogram OR LVEF >= 50% by gated radionuclide study - Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled - No CNS toxicity > grade 2 - No serious intercurrent illnesses - No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs - No peripheral neuropathy > grade 1 - No known hypersensitivity to bortezomib, boron, or mannitol - No other concurrent chemotherapy or immunomodulating agents (including steroids) - Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions - No dexamethasone or aprepitant as an antiemetic - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Recovered from prior therapy - No prior bortezomib or other proteasome inhibitors - At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas) - More than 14 days since prior investigational drugs - No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants - Benzodiazepine or gabapentin allowed |
Country | Name | City | State |
---|---|---|---|
United States | Children's Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response (CR) | CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging. | After 2 cycles of treatment | |
Secondary | Number of Participants With Grade 3 or 4 Toxicity | Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy | 4 weeks following completion of therapy | |
Secondary | Overall Response Rate | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR | After 2 cycles and 4 cycles | |
Secondary | Induction Success Rate | Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to < grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of >2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.) | After 2 cycles and 4 cycles | |
Secondary | Rate of Successful PBSC Harvest | Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days. | After 2 cycles | |
Secondary | Biological Markers | Assessing baseline NF-kB protein levels in tumor tissue | Before, during, and after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02168140 -
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01902160 -
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT01165112 -
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Completed |
NCT00132028 -
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00005803 -
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT02240719 -
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
|
Phase 1 | |
Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00098891 -
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Completed |
NCT01460940 -
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT01476839 -
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01748721 -
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Terminated |
NCT00101244 -
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00105001 -
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
Phase 2 |